Please login to the form below

Not currently logged in
Email:
Password:

Tanzeum

This page shows the latest Tanzeum news and features for those working in and with pharma, biotech and healthcare.

Sanofi's lixisenatide is back under FDA review

Sanofi's lixisenatide is back under FDA review

Meanwhile, new GLP-1 agonists that require dosing just once a week - including Eli Lilly's Trulicity (dulaglutide), GlaxoSmithKline's Tanzeum (albiglutide) AstraZeneca's Bydureon (exenatide) and Novo Nordisk's semaglutide -

Latest news

  • Type 2 diabetes market set to hit $39bn by 2021 Type 2 diabetes market set to hit $39bn by 2021

    Notable examples include two recently approved once-weekly GLP-1 receptor agonists, Tanzeum and Trulicity, and an orally administered GLP-1 receptor agonist, OG-217SC, which is in phase II development,

  • Novo Nordisk's oral GLP-1 analogue looks set for phase III Novo Nordisk's oral GLP-1 analogue looks set for phase III

    If the injectable version is approved it will have to compete with a number of similar products on the market - notably AstraZeneca's Bydureon (exenatide), GlaxoSmithKline's Tanzeum/Eperzan (albiglutide) and

  • Novo Nordisk's Xultophy debuts in Switzerland Novo Nordisk's Xultophy debuts in Switzerland

    s Tanzeum (albiglutide), AstraZeneca's Bydureon (exenatide) and Eli Lilly's recently-launched Trulicity (dulaglutide) offering once-weekly rather than once-daily injections.

  • Lilly launches GLP-1 agonist Trulicity in US Lilly launches GLP-1 agonist Trulicity in US

    Lilly launches GLP-1 agonist Trulicity in US. Once-weekly treatment will challenge GSK's Tanzeum, AZ's Bydureon and Novo's Victoza in diabetes. ... Lilly has launched Trulicity in the same price region as Victoza but above Tanzeum, which GSK is selling

  • FDA approves Lilly’s GLP-1 diabetes drug Trulicity FDA approves Lilly’s GLP-1 diabetes drug Trulicity

    FDA approves Lilly’ s GLP-1 diabetes drug Trulicity. The once-weekly treatment is set to compete with Bydureon, Tanzeum and Victoza. ... Competition is heating up, however, and GlaxoSmithKline has won approval for once-weekly albiglutide in the US

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics